tradingkey.logo
tradingkey.logo
Suchen

Journey Medical Corp

DERM
Zur Watchlist hinzufügen
6.250USD
-0.080-1.26%
Handelsschluss 05/18, 16:00ETKurse um 15 Minuten verzögert
134.59MMarktkapitalisierung
VerlustKGV TTM

Journey Medical Corp

6.250
-0.080-1.26%

mehr Informationen über Journey Medical Corp Unternehmen

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp Informationen

BörsenkürzelDERM
Name des UnternehmensJourney Medical Corp
IPO-datumNov 12, 2021
CEOMaraoui (Claude)
Anzahl der mitarbeiter41
WertpapierartOrdinary Share
GeschäftsjahresendeNov 12
Addresse9237 E Via De Ventura Blvd., Suite 105
StadtSCOTTSDALE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl85258
Telefon14804346670
Websitehttps://journeymedicalcorp.com/
BörsenkürzelDERM
IPO-datumNov 12, 2021
CEOMaraoui (Claude)

Führungskräfte von Journey Medical Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
10.00K
-471.73%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%
Nach RegionUSD
Name
Umsatz
Anteil
United States
61.86M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%

Aktionärsstatistik

Aktualisiert: Wed, May 13
Aktualisiert: Wed, May 13
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Andere
49.78%
Aktionäre
Aktionäre
Anteil
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Andere
49.78%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
21.80%
Investment Advisor/Hedge Fund
17.26%
Individual Investor
16.85%
Investment Advisor
16.39%
Corporation
15.74%
Private Equity
2.08%
Insurance Company
0.88%
Research Firm
0.44%
Pension Fund
0.24%
Andere
8.31%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
137
12.08M
56.62%
+2.74M
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fortress Biotech Inc
3.36M
15.75%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.66%
+1.24M
+150.79%
Aug 25, 2025
Wasatch Global Investors Inc
1.32M
6.17%
+10.00K
+0.77%
Dec 31, 2025
Tang Capital Management, LLC
1.85M
8.69%
--
--
Dec 31, 2025
Opaleye Management Inc.
975.00K
4.57%
+3.94K
+0.41%
Dec 31, 2025
J. Goldman & Co., L.P.
798.37K
3.74%
+798.37K
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
655.76K
3.07%
+83.84K
+14.66%
Dec 31, 2025
Alloush (Ramsey)
316.68K
1.48%
+46.86K
+17.37%
Jun 17, 2025
Millennium Management LLC
457.81K
2.15%
+457.81K
--
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Royce Quant Small-Cap Quality Value ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI